Literature DB >> 27875247

Comorbidity prevalence, healthcare utilization, and expenditures of Medicaid enrolled adults with autism spectrum disorders.

Rini Vohra1, Suresh Madhavan1, Usha Sambamoorthi1.   

Abstract

A retrospective data analysis using 2000-2008 three state Medicaid Analytic eXtract was conducted to examine the prevalence and association of comorbidities (psychiatric and non-psychiatric) with healthcare utilization and expenditures of fee-for-service enrolled adults (22-64 years) with and without autism spectrum disorders (International Classification of Diseases, Ninth Revision-clinical modification code: 299.xx). Autism spectrum disorder cases were 1:3 matched to no autism spectrum disorder controls by age, gender, and race using propensity scores. Study outcomes were all-cause healthcare utilization (outpatient office visits, inpatient hospitalizations, emergency room, and prescription drug use) and associated healthcare expenditures. Bivariate analyses (chi-square tests and t-tests), multinomial logistic regressions (healthcare utilization), and generalized linear models with gamma distribution (expenditures) were used. Adults with autism spectrum disorders (n = 1772) had significantly higher rates of psychiatric comorbidity (81%), epilepsy (22%), infections (22%), skin disorders (21%), and hearing impairments (18%). Adults with autism spectrum disorders had higher mean annual outpatient office visits (32ASD vs 8noASD) and prescription drug use claims (51ASD vs 24noASD) as well as higher mean annual outpatient office visits (US$4375ASD vs US$824noASD), emergency room (US$15,929ASD vs US$2598noASD), prescription drug use (US$6067ASD vs US$3144noASD), and total expenditures (US$13,700ASD vs US$8560noASD). The presence of a psychiatric and a non-psychiatric comorbidity among adults with autism spectrum disorders increased the annual total expenditures by US$4952 and US$5084, respectively.

Entities:  

Keywords:  Medicaid; autism spectrum disorders; economic costs; healthcare expenditures; healthcare utilization; medical comorbidity; psychiatric comorbidity

Mesh:

Year:  2016        PMID: 27875247      PMCID: PMC5517354          DOI: 10.1177/1362361316665222

Source DB:  PubMed          Journal:  Autism        ISSN: 1362-3613


  65 in total

1.  Use and cost of psychotropic drugs among recipients with autism in a state Medicaid fee-for-service programme.

Authors:  R Khanna; K Jariwala; D West-Strum
Journal:  J Intellect Disabil Res       Date:  2012-04-04

2.  Home- and community-based waivers for children with autism: effects on service use and costs.

Authors:  Zuleyha Cidav; Steven C Marcus; David S Mandell
Journal:  Intellect Dev Disabil       Date:  2014-08

Review 3.  Overview of meta-analyses on early intensive behavioral intervention for young children with autism spectrum disorders.

Authors:  Brian Reichow
Journal:  J Autism Dev Disord       Date:  2012-04

4.  Brief report: the medical care of adults with autism spectrum disorders: identifying the needs.

Authors:  Mary Beth Bruder; Gerard Kerins; Cynthia Mazzarella; Jessica Sims; Neil Stein
Journal:  J Autism Dev Disord       Date:  2012-11

5.  Access and service use by children with autism spectrum disorders in Medicaid Managed Care.

Authors:  Lisa A Ruble; Craig Anne Heflinger; J William Renfrew; Robert C Saunders
Journal:  J Autism Dev Disord       Date:  2005-02

Review 6.  An update on pharmacotherapy for autism spectrum disorder in children and adolescents.

Authors:  Na Young Ji; Robert L Findling
Journal:  Curr Opin Psychiatry       Date:  2015-03       Impact factor: 4.741

7.  A national profile of the health care experiences and family impact of autism spectrum disorder among children in the United States, 2005-2006.

Authors:  Michael D Kogan; Bonnie B Strickland; Stephen J Blumberg; Gopal K Singh; James M Perrin; Peter C van Dyck
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

Review 8.  Metabolic syndrome and obesity among users of second generation antipsychotics: A global challenge for modern psychopharmacology.

Authors:  Leonel E Rojo; Pablo A Gaspar; H Silva; L Risco; Pamela Arena; Karen Cubillos-Robles; Belen Jara
Journal:  Pharmacol Res       Date:  2015-07-26       Impact factor: 7.658

Review 9.  Costs of autism spectrum disorders in the United Kingdom and the United States.

Authors:  Ariane V S Buescher; Zuleyha Cidav; Martin Knapp; David S Mandell
Journal:  JAMA Pediatr       Date:  2014-08       Impact factor: 16.193

10.  Personality characteristics of adults with autism spectrum disorders or attention deficit hyperactivity disorder with and without substance use disorders.

Authors:  Bram Sizoo; Wim van den Brink; Marielle Gorissen van Eenige; Rutger Jan van der Gaag
Journal:  J Nerv Ment Dis       Date:  2009-06       Impact factor: 2.254

View more
  44 in total

Review 1.  Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder.

Authors:  Robyn P Thom; Christopher J Keary; Michelle L Palumbo; Caitlin T Ravichandran; Jennifer E Mullett; Eric P Hazen; Ann M Neumeyer; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

2.  Rates of Co-occurring Psychiatric Disorders in Autism Spectrum Disorder Using the Mini International Neuropsychiatric Interview.

Authors:  Maya G Mosner; Jessica L Kinard; Jasmine S Shah; Sean McWeeny; Rachel K Greene; Sarah C Lowery; Carla A Mazefsky; Gabriel S Dichter
Journal:  J Autism Dev Disord       Date:  2019-09

3.  Service use by youth with autism within a system-driven implementation of evidence-based practices in children's mental health services.

Authors:  Nicole A Stadnick; Anna S Lau; Kelsey S Dickson; Keri Pesanti; Debbie Innes-Gomberg; Lauren Brookman-Frazee
Journal:  Autism       Date:  2020-07-18

4.  Sex Differences in Social Participation of High School Students with Autism Spectrum Disorder.

Authors:  Leann Smith DaWalt; Julie Lounds Taylor; Somer Bishop; Laura J Hall; Jessica Dykstra Steinbrenner; Bonnie Kraemer; Kara A Hume; Samuel L Odom
Journal:  Autism Res       Date:  2020-09-02       Impact factor: 5.216

5.  Objective Estimates of Direct-Medical Costs Among Persons Aged 3 to 38 Years With and Without Research-Defined Autism Spectrum Disorder Ascertained During Childhood: A Population-Based Birth-Cohort Study.

Authors:  Cynthia Leibson; Amy Weaver; Scott Myers; Kirsten Long; Jeanine Ransom; Robert Voigt; Slavica Katusic
Journal:  Value Health       Date:  2020-02-27       Impact factor: 5.725

Review 6.  The Economic Costs of Autism Spectrum Disorder: A Literature Review.

Authors:  Nicky Rogge; Juliette Janssen
Journal:  J Autism Dev Disord       Date:  2019-07

7.  Association Between Prematurity and Diagnosis of Neurodevelopment Disorder: A Case-Control Study.

Authors:  Thaise C B Soncini; Gabriella Antunes Belotto; Alexandre P Diaz
Journal:  J Autism Dev Disord       Date:  2020-01

8.  Increased prevalence of non-communicable physical health conditions among autistic adults.

Authors:  Elizabeth Weir; Carrie Allison; Varun Warrier; Simon Baron-Cohen
Journal:  Autism       Date:  2020-09-09

9.  States' use of Medicaid to meet the needs of autistic individuals.

Authors:  Lindsay Lawer Shea; Kaitlin H Koffer Miller; Kate Verstreate; Sha Tao; David Mandell
Journal:  Health Serv Res       Date:  2021-07-12       Impact factor: 3.402

10.  Measuring Depression in Autistic Adults: Psychometric Validation of the Beck Depression Inventory-II.

Authors:  Zachary J Williams; Jonas Everaert; Katherine O Gotham
Journal:  Assessment       Date:  2020-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.